trackpaw scientific ab

TrackPaw Scientific's deep tech solution for 24/7 monitoring of early stage pharmaceutical development offers improved animal welfare together with better study outcomes.

Proteas Bioanalytics Inc.

From a single drop of blood, Proteas Bioanalytics is able to detect the presence of human diseases at their earliest stage, before the onset of symptoms. Our technologies will also provide objective guidance to implement effective treatment options. Proteas Bioanalytics has also developed advanced technologies for the in-depth analysis and biological understanding of single cells and tissue biopsy specimens that complement and validates our blood-based analysis platform. The field of blood and single-cell proteomics offers a tremendous opportunity to reshape the diagnosis and treatment of almost all diseases. Currently used proteomics technologies do not meet the stringent FDA performance criteria due to the high complexity and heterogeneity of human blood, tissue and cells and their analysis method. The Proteas Bioanalytics proprietary proteomics technology: ▪ includes the analysis of all proteins expressed in blood, cells and tissues during healthy or diseased situations ▪ leverages 30-years of our published methods and overcomes previous limitations ▪ leads to the development of novel protein-based biological signatures with actionable clinical importance ▪ leads to the development of novel proteins markers for monitoring the response to treatment (pharmacology, immunotherapy, nutritional intervention, lifestyle intervention) ➢ We are both a platform and disease-specific biosignature with assay development company ➢ Our core proteomics technology can be partnered across indications to pharma and biotech companies, while our internal biomarker platforms will be developed for high unmet needs in the clinical arena The Proteas Bioanalytics team has extensive industrial, academic, and government experience in research and development, partnering, biology, pharmacology, analytical chemistry, nanotechnology, mathematics and artificial intelligence that will promotes the development of a state-of-the-art and innovative platforms.

Oligomer Biotechnology

Oligomer's mission is to maintain and when required surpass global standards and provide world-class products and services with an always open and friendly attitude. Oligomer has been providing biotechnological products and services within Eurasia and the MENA region to a customer portfolio composed of universities, research institutes, genetic diagnosis and in vitro fertilization centers. Our products and services mostly support researches in the fields of health, nutrition, agriculture, environment and education.

Evolute Bioscience

Evolute Bioscience is an initiative by NIT alumini to establish a technicalized environment that focus on the research needs and prepare the students to meet the industrial requirements in biotechnology. This is a startup organization aims to provide technical hands-on opportunities to students pursuing undergraduate & post graduate studies in life science, pharma and biotechnology also to furnish an environment to effectively utilize lab facilities for research scholars. Our focus is to bridge the gap between theoretical learning and practical implementation by introducing all possible technical resources to the students. The preliminary work of the organization is to cater the research gaps and train the students accordingly for industrial employment.

Genefitletics

Genefitletics, a biotech company founded in 2019, uses system biology & mathematics to accelerate the speed at which application of scientific discoveries & molecular data driven personalization empowers people to reclaim control of their health Harnessing the power of next generation sequencing, cloud computing & machine learning, Genefitletics's system biology platform measures & analyzes biology & chemistry of an individual at molecular level to deeply understand origin & progression of chronic diseases in order to prevent, diagnose them early, stop their progression and reverse them. This data driven platform that precisely characterize human-microbial interactions : 1)Provide patients with unique molecular insights & precision nutrition interventions to bring their body back into homeostasis 2)Give healthcare practitioners access to hard to detect pre disease signals which conventional clinical diagnostic tests cannot identify, enabling them to align their interventions with patient’s unique biochemical individuality The company is led by a team of researchers, inventors, industry experts & passionate & curious entrepreneurs with a combined leadership & executive experience of 30 + years who are on a journey to impact human health. The company has been awarded as : 1) Best chronic illness prevention R &D Biotech company 2024-South Asia by Global Health & Pharma 2)Biotech Innovation Excellence Award 2024- by Global Heath & Pharma 3)Microbiome Therapeutics as a service platform, 2023 by AWS & MINFY in association with CNBC 4)Chronic Illness Prevention R&D Biotech Company- Asia,2022 by Global Health Pharma 5)Specialist Biotech Company of the year, CorporateLiveWire, Global Awards, 2022/23 6) Microbiome Therapeutics as a service platform, 2023 by Global Health & Pharma 7) Chronic Illness Prevention R&D Biotech Company of the Year 2023 - Asia by AI Global Media